Assetmark Inc. Has $10.45 Million Holdings in The Cooper Companies, Inc. $COO

Assetmark Inc. increased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 24,565.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 152,430 shares of the medical device company’s stock after buying an additional 151,812 shares during the period. Assetmark Inc. owned 0.08% of Cooper Companies worth $10,451,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wealth Alliance LLC lifted its stake in shares of Cooper Companies by 4.2% in the 2nd quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after purchasing an additional 171 shares during the period. Pacer Advisors Inc. increased its holdings in Cooper Companies by 0.8% in the third quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock worth $1,582,000 after purchasing an additional 182 shares in the last quarter. Citizens Financial Group Inc. RI increased its holdings in Cooper Companies by 2.7% in the third quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock worth $492,000 after purchasing an additional 192 shares in the last quarter. State of Michigan Retirement System lifted its stake in Cooper Companies by 0.4% in the second quarter. State of Michigan Retirement System now owns 54,344 shares of the medical device company’s stock valued at $3,867,000 after buying an additional 200 shares during the period. Finally, New York Life Investment Management LLC boosted its holdings in shares of Cooper Companies by 0.7% during the 2nd quarter. New York Life Investment Management LLC now owns 30,019 shares of the medical device company’s stock worth $2,136,000 after buying an additional 210 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Piper Sandler reiterated an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Barclays set a $98.00 price objective on shares of Cooper Companies and gave the stock an “overweight” rating in a research report on Monday, January 26th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $73.00 price target on shares of Cooper Companies in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $90.77.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Maria Rivas bought 1,000 shares of Cooper Companies stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $82.13 per share, with a total value of $82,130.00. Following the completion of the acquisition, the director directly owned 11,141 shares in the company, valued at approximately $915,010.33. The trade was a 9.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Albert G. White III purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were acquired at an average cost of $80.80 per share, with a total value of $808,000.00. Following the completion of the transaction, the chief executive officer directly owned 236,151 shares of the company’s stock, valued at $19,081,000.80. The trade was a 4.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 16,014 shares of company stock valued at $1,304,416 in the last quarter. 1.98% of the stock is owned by company insiders.

Cooper Companies Stock Performance

Shares of COO opened at $82.99 on Monday. The firm has a market capitalization of $16.26 billion, a P/E ratio of 44.14, a P/E/G ratio of 2.37 and a beta of 1.03. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $93.00. The stock has a 50 day moving average price of $81.83 and a two-hundred day moving average price of $74.84. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the firm earned $1.04 earnings per share. Cooper Companies’s quarterly revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.